Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine

被引:0
|
作者
Milagres, LG [1 ]
Brandileone, MCC [1 ]
Sacchi, CT [1 ]
Vieira, VSD [1 ]
Zanella, RC [1 ]
Frasch, CE [1 ]
机构
[1] US FDA, CTR BIOL EVALUAT & RES, BETHESDA, MD 20892 USA
来源
关键词
Neisseria meningitidis; lipooligosaccharide; vaccine; iron regulated protein; outer membrane;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Since 1988, N. meningitis, B:4:P1.15, ET-5 complex, has been responsible for an epidemic of meningococcal disease in Greater Sao Paulo, Brazil. Despite current trials to develop an effective vaccine against group B meningococci, children less than 2 years old have not been protected. It has been suggested that iron-regulated proteins (IRPs) should be considered as potential antigens for meningococcal vaccines. The vaccines under study consisted of outer-membrane vesicles depleted of lipooligosaccharide from three serogroup B strains and one serogroup C strain, IRPs, meningococcal group C polysaccharide and aluminum hydroxide. Four different protein and C: polysaccharide concentrations were studied. The ELISA and bactericidal results showed a higher antibody response when 2 injections of 2.0 mu g doses were administered. Despite higher IgG reactivity against antigen preparations-containing IRPs seen in ELISA, the bactericidal activity was not increased if the target strain was grown in iron-restricted medium, The influence of addition of alkaline-detoxified lipooligosaccharide (dLOS) on immunogenicity of the vaccine was also investigated, and the dLOS provided for a functionally specific antibody response.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 50 条
  • [1] HUMAN-ANTIBODY RESPONSES TO MENINGOCOCCAL OUTER-MEMBRANE ANTIGENS AFTER 3 DOSES OF THE NORWEGIAN GROUP-B MENINGOCOCCAL VACCINE
    ROSENQVIST, E
    HOIBY, EA
    WEDEGE, E
    BRYN, K
    KOLBERG, J
    KLEM, A
    RONNILD, E
    BJUNE, G
    NOKLEBY, H
    INFECTION AND IMMUNITY, 1995, 63 (12) : 4642 - 4652
  • [2] ANTIBODY-RESPONSES TO SEROGROUP-B MENINGOCOCCAL OUTER-MEMBRANE ANTIGENS AFTER VACCINATION AND INFECTION
    ROSENQVIST, E
    HARTHUG, S
    FROHOLM, LO
    HOIBY, EA
    BOVRE, K
    ZOLLINGER, WD
    JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (08) : 1543 - 1548
  • [3] A MENINGOCOCCAL NATIVE OUTER MEMBRANE VESICLE VACCINE AS A PLATFORM FOR PRESENTING CONSERVED GONOCOCCAL ANTIGENS
    Moe, Gregory
    Beernink, Peter
    Vianzon, Vianca
    SEXUALLY TRANSMITTED INFECTIONS, 2019, 95 : A38 - A38
  • [4] Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine
    Zollinger, Wendell D.
    Donets, Mikhail A.
    Schmiel, Deborah H.
    Pinto, Valerian B.
    Labrie, Joseph E., III
    Moran, Elizabeth E.
    Brandt, Brenda L.
    Ionin, Boris
    Marques, Ryan
    Wu, Max
    Chen, Ping
    Stoddard, Mark B.
    Keiser, Paul B.
    VACCINE, 2010, 28 (31) : 5057 - 5067
  • [5] STUDIES ON MITOGENICITY AND ADJUVANTICITY OF MENINGOCOCCAL OUTER-MEMBRANE PROTEINS IN MICE
    SOLOW, RS
    SODD, MA
    ZOLLINGER, WD
    LOWELL, GH
    FEDERATION PROCEEDINGS, 1982, 41 (03) : 830 - 830
  • [6] Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic
    Aaberge, IS
    Oster, P
    Helland, OS
    Kristoffersen, AC
    Ypma, E
    Hoiby, EA
    Feiring, B
    Nokleby, H
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (05) : 599 - 605
  • [7] Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles
    Bai, Xilian
    Findlow, Jamie
    Borrow, Ray
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (07) : 969 - 985
  • [8] Antibody avidity and immunoglobulin G Isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine
    Vermont, CL
    van Dijken, HH
    van Limpt, CJP
    de Groot, R
    van Alphen, L
    van den Dobbelsteen, GPJM
    INFECTION AND IMMUNITY, 2002, 70 (02) : 584 - 590
  • [9] Antibody specificities and effect of meningococcal carriage in Icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine
    Wedege, E
    Kuipers, B
    Bolstad, K
    van Dijken, H
    Froholm, LO
    Vermont, C
    Caugant, DA
    van den Dobbelsteen, G
    INFECTION AND IMMUNITY, 2003, 71 (07) : 3775 - 3781
  • [10] Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine
    Milagres, LG
    Gorla, MCA
    Sacchi, CT
    Rodrigues, MM
    INFECTION AND IMMUNITY, 1998, 66 (10) : 4755 - 4761